I have listened to the conference call several times and taken accurate notes and combined with recent press release, I believe a reversal is a solid 50/50 chance or perhaps an approval to file black with a small concurrent easy trial.
Ampion is almost historic in that in that there has not been even one single adverse side effect in thousands of patients.
It has also repeatedly met endpoints.
Time will soon tell, but I m betting on a reversal.
News 
Market Data 
Discover 
